• Merck presented one-year results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig for diabetic macular edema at AAO 2026.
• Both dose regimens achieved vision outcomes comparable to monthly ranibizumab, meeting the study’s main goal without showing an advantage.
• Safety flagged more proliferative diabetic retinopathy events and more treatment stops in remigromig arms versus ranibizumab.
• Merck plans regulatory discussions, with additional pivotal data expected from the ongoing BAROLO study in diabetic macular edema.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261010000066) on October 10, 2026, and is solely responsible for the information contained therein.